Adaptive Licensing and Conditional Approval: A Perspective on Evidence Owed After Market Entry. Translational Medicine & Therapeutics Journal, [S. l.], v. 2, n. 2, p. 92–100, 2023. DOI: 10.5281/zenodo.22649112. Disponível em: https://inkwise.org/index.php/TMTJ/article/view/87. Acesso em: 5 nov. 2026.